Clinical Value of 89Zr-trastuzumab PET

HER2-PET as a Diagnostic Tool in Breast Cancer Patients With a Clinical Dilemma

Information about the presence of human epidermal growth factor receptor 2 (HER2) in tumor lesions in breast cancer patients is essential for diagnostic and therapeutic management of metastatic breast cancer. In daily practice however, obtaining a metastasis biopsy can be difficult or impracticable. Therefore, clinicians can be faced with a persistent clinical dilemma in some breast cancer patients, leading to suboptimal therapy decisions due to lack of HER2 receptor information. Circulating tumor cells (CTCs), which may provide additional information, have so far not been able to replace the biopsy. To solve this problem, non-invasive whole body visualization and quantification of HER2 expression by means of the HER2-PET may be a valuable tool.

In this prospective multicenter imaging study, eligible patients will receive one HER2-PET and CTC analysis in addition to standard work up for metastatic disease. Subsequent administration of anti-HER2 therapy will be evaluated. Referring physicians fill in three questionnaires, one before HER2-PET and two after HER2-PET.

Study Overview

• Status: Completed
• Conditions: Metastatic Breast Cancer
• Intervention / Treatment: Drug: 89Zr-trastuzumab injection

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Phase 2

Contacts and Locations

Study Locations

• Netherlands
  • Groningen, Netherlands
    • University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

1. Patients with a history of histological and/or cytological proven HER2-positive primary breast cancer. In the Netherlands HER2-positivity is defined as:

   • HER2 immunohistochemical score of 3+, or
   • HER2 immunohistochemical score of 2+ and positive FISH for HER2/c-erbB2 amplification.

   In Belgium HER2-positivity is defined as positive FISH for HER2/c-erbB2 amplification.

2. Patients with suspected metastatic disease or local recurrence of HER2-positive breast cancer and a clinical dilemma:

   • in whom standard work up with imaging has failed to solve the clinical dilemma (diagnostic/therapeutic), leaving issues with regard to HER2 status of lesions and
   • in whom a biopsy is desirable but cannot (easily) be performed due to technical or patient factors or otherwise.
3. Standard work-up with imaging is defined as CT chest and abdomen, bone scintigraphy, as well as FDG-PET.
4. Age >18 years of age.
5. WHO performance status 0-2.
6. Signed written informed consent.
7. Able to comply with the protocol.

Exclusion Criteria:

1. Pregnant or lactating women.
2. Prior allergic reaction to immunoglobulins or immunoglobulin allergy.
3. Inability to comply with study procedures

Study Plan

How is the study designed?

Design Details

• Primary Purpose: DIAGNOSTIC
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: HER2-PET; Injection of 89Zr-trastuzumab followed by PET scan	Drug: 89Zr-trastuzumab injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Concordance between HER2-PET results and anti-HER2 therapy	Concordance between HER2-PET results and anti-HER2 therapy is defined as HER2 positive lesion(s) on HER2-PET and subsequent anti-HER2 therapy; or no HER2 positive lesions on HER2-PET and no subsequent anti-HER2 therapy. It is considered a clinically relevant contribution of HER2-PET to anti-HER2-therapy decisions if there is a concordance in at least 2/3 of included patients.	about 2 years (end of study)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Correlation of HER2-PET results and questionnaire results regarding clinical value of HER2-PET for the referring clinician	Correlation of HER2-PET result (assessed about 1 week after scan) and questionnaire results (before, directly after, and 3 months after scan)	about 2 years (end of study)
Correlation of HER2-PET results with standard conventional work-up	Correlation of HER2-PET result (assessed about 1 week after scan) and standard conventional work-up (assessed before/at screening)	about 2 years (end of study)
Correlation of HER2-PET results and HER-2 expression by CTCs	Correlation of HER2-PET result (assessed about 1 week after scan) and HER-2 expression by CTCs (blood for CTC analysis will be drawn at day of tracer injection, analysis within 3 days)	about 2 years (end of study)

Collaborators and Investigators

• Sponsor: University Medical Center Groningen

Study record dates

Study Major Dates

• Study Start: March 1, 2013
• Primary Completion (ACTUAL): June 1, 2015
• Study Completion (ACTUAL): October 1, 2015

Study Registration Dates

• First Submitted: April 3, 2013
• First Submitted That Met QC Criteria: April 10, 2013
• First Posted (ESTIMATE): April 15, 2013

Study Record Updates

• Last Update Posted (ESTIMATE): November 5, 2015
• Last Update Submitted That Met QC Criteria: November 4, 2015
• Last Verified: November 1, 2015

More Information

Terms related to this study

• Keywords: metastatic breast cancer; HER2-PET; 89Zr-trastuzumab; clinical dilemma
• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Antineoplastic Agents; Antineoplastic Agents, Immunological; Trastuzumab
• Other Study ID Numbers: Her2.4